Immatics任命行业资深人士为首席财务官

2025-10-01 20:14

Immatics N.V. (NASDAQ:IMTX) has appointed Venkat Ramanan as chief financial officer, effective immediately.
Ramanan brings 25+ years of biopharma finance experience, with leadership roles at Seagen, Gilead (GILD), Amgen (AMGN), and most recently as CFO at Anthos Therapeutics, acquired by Novartis in April 2025.
Ramanan succeeds Arnd Christ.
Ramanan will help lead commercial preparations for Immatics’ lead PRAME-targeting cell therapy, anzu-cel, in metastatic melanoma.
Source: Press release

More on Immatics